IPP Bureau

Bayer welcomes the U.S. Supreme Court decision to review Durnell case in the Roundup litigation
Bayer welcomes the U.S. Supreme Court decision to review Durnell case in the Roundup litigation

By IPP Bureau - January 17, 2026

Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy

HDFC Bank to rally 1,500 staff at Tata Mumbai Marathon 2026 to drive cancer awareness
HDFC Bank to rally 1,500 staff at Tata Mumbai Marathon 2026 to drive cancer awareness

By IPP Bureau - January 17, 2026

The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society

EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy
EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy

By IPP Bureau - January 17, 2026

Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike

Rakuten Medical teams up with LOTTE Biologics to boost production of innovative cancer therapy
Rakuten Medical teams up with LOTTE Biologics to boost production of innovative cancer therapy

By IPP Bureau - January 17, 2026

LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates

Agno Pharma acquires Actylis Eugene, expanding US API manufacturing footprint
Agno Pharma acquires Actylis Eugene, expanding US API manufacturing footprint

By IPP Bureau - January 17, 2026

The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility

Gradalis’ Vigil therapy dramatically extends survival in advanced ovarian cancer
Gradalis’ Vigil therapy dramatically extends survival in advanced ovarian cancer

By IPP Bureau - January 17, 2026

The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer

Boston Scientific to acquire Penumbra in $14.5 billion deal
Boston Scientific to acquire Penumbra in $14.5 billion deal

By IPP Bureau - January 17, 2026

Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion

Miach Orthopaedics’ BEAR implant gains FDA label claim for reduced arthritis risk
Miach Orthopaedics’ BEAR implant gains FDA label claim for reduced arthritis risk

By IPP Bureau - January 17, 2026

The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk

GCCL & OPIS forge global clinical trial alliance
GCCL & OPIS forge global clinical trial alliance

By IPP Bureau - January 17, 2026

WuXi Biologics launches PatroLab digital twin platform to transform biologics manufacturing
WuXi Biologics launches PatroLab digital twin platform to transform biologics manufacturing

By IPP Bureau - January 16, 2026

The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing

Alphatec and Theradaptive forge landmark spine partnership as Series B round launches
Alphatec and Theradaptive forge landmark spine partnership as Series B round launches

By IPP Bureau - January 16, 2026

ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications

Redesigned brain receptor drugs show promise for depression
Redesigned brain receptor drugs show promise for depression

By IPP Bureau - January 16, 2026

The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold

AVEO Oncology doses first patient in pioneering AML clinical trial
AVEO Oncology doses first patient in pioneering AML clinical trial

By IPP Bureau - January 16, 2026

The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy

Gabby Union-Wade fronts Bayer's new menopause drug, Lynkuet
Gabby Union-Wade fronts Bayer's new menopause drug, Lynkuet

By IPP Bureau - January 16, 2026

The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign

Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia
Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia

By IPP Bureau - January 16, 2026

Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination

Latest Stories

Interviews

Packaging